**Background**
The proteasome is a large multi-subunit protease complex responsible for the degradation of ubiquitinated proteins, playing a critical role in maintaining cellular protein homeostasis. Dysregulation of the ubiquitin-proteasome system is frequently observed in various pathologies, particularly in cancer, where the degradation of tumor suppressors or the stabilization of oncoproteins drives malignancy. By inhibiting the proteasome, it is possible to block the degradation of key regulatory proteins, such as p53, thereby triggering programmed cell death. Given its ability to modulate protein turnover and induce apoptosis, the proteasome has become a primary target for therapeutic intervention in MG-115 cancer research. In this context, we will introduce a potent and reversible proteasome inhibitor – MG-115.
**Definition**
MG-115 is a reversible proteasome inhibitor that specifically targets the chymotrypsin-like activity of the proteasome, exhibiting $K_i$ values of 21 nM for the 20S proteasome and 35 nM for the 26S proteasome.
**In Vitro Studies**
According to the MG-115 description, this compound is designed to inhibit proteasomal activity and induce p53-dependent apoptosis. In terms of MG-115 biological activity, in vitro studies have demonstrated its efficacy in various cellular models. Specifically, MG-115 (0.1-10 μM; 24 h) was found to decrease the viability of HepG2 cells in a dose-dependent manner, with an $\text{IC}_{50}$ of 2 μM for the inhibition of proteasomal activity. Furthermore, treatment with MG-115 (0.1-10 μM; 24 h) has been shown to amplify reporter gene expression mediated by CWK 18 DNA condensates. These results highlight the compound’s ability to modulate cellular viability and gene expression by targeting the proteasome pathway. In conclusion, MG-115 is a potent and reversible proteasome inhibitor suitable for studying protein degradation and apoptosis.
Keywords
MG-115, 133407-86-0, MG115, MG 115, Proteasome, Apoptosis, 20S, 26S, apoptosis, Inhibitor, inhibitor, inhibit
References
[1] Rock KL, et, al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761-71.
[2] Lopes UG, et, al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997 May 16;272(20):12893-6.
[3] Kim J, et, al. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther. 2005 Nov;12(21):1581-90.